Is CEREBROVASCULAR ACCIDENT a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed CEREBROVASCULAR ACCIDENT.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 24 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported CEREBROVASCULAR ACCIDENT to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and CEREBROVASCULAR ACCIDENT. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause CEREBROVASCULAR ACCIDENT, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes CEREBROVASCULAR ACCIDENT. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if CEREBROVASCULAR ACCIDENT ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing CEREBROVASCULAR ACCIDENT: 24
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where CEREBROVASCULAR ACCIDENT is a reported side effect: 0.7209%

FDA reports of any drug causing CEREBROVASCULAR ACCIDENT : 80839
Average percentage for all medicated patients where CEREBROVASCULAR ACCIDENT is reported as a complication: 0.5067%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with CEREBROVASCULAR ACCIDENT:

VIOXX (32103 patients)
AVANDIA (7615 patients)
ASPIRIN (6908 patients)
CELEBREX (5338 patients)
BEXTRA (3812 patients)
LIPITOR (3624 patients)
PLAVIX (3248 patients)
AVONEX (2478 patients)
FOSAMAX (2310 patients)
LASIX (2164 patients)
YAZ (2135 patients)
TRASYLOL (2082 patients)
LISINOPRIL (2031 patients)
NEXIUM (2008 patients)
YASMIN (1976 patients)
COUMADIN (1970 patients)
ZOCOR (1853 patients)
NORVASC (1787 patients)
ATENOLOL (1703 patients)
PREMARIN (1657 patients)
HEPARIN SODIUM INJECTION (1624 patients)
SYNTHROID (1607 patients)
DIANEAL (1551 patients)
HYDROCHLOROTHIAZIDE (1535 patients)
NEURONTIN (1530 patients)
SEROQUEL (1512 patients)
SIMVASTATIN (1493 patients)
TOPROL-XL (1459 patients)
FORTEO (1454 patients)
PREDNISONE (1454 patients)
LANTUS (1377 patients)
FUROSEMIDE (1330 patients)
DIOVAN (1327 patients)
[THERAPY UNSPECIFIED] (1319 patients)
PRILOSEC (1271 patients)
HUMIRA (1231 patients)
INSULIN (1220 patients)
DIGOXIN (1218 patients)
PRADAXA (1190 patients)
ZOLOFT (1139 patients)
GLUCOPHAGE (1139 patients)
CRESTOR (1111 patients)
FOLIC ACID (1102 patients)
AVANDAMET (1040 patients)
PROTONIX (1035 patients)
XANAX (1014 patients)
METHOTREXATE (1012 patients)
OMEPRAZOLE (1004 patients)
PREVACID (998 patients)
METFORMIN HCL (975 patients)
IBUPROFEN (973 patients)
TYLENOL (CAPLET) (965 patients)
AMBIEN (954 patients)
HEPARIN (932 patients)
HUMALOG (928 patients)
NITROGLYCERIN (920 patients)
REMICADE (919 patients)
ACETAMINOPHEN (911 patients)
ALBUTEROL (886 patients)
LUCENTIS (865 patients)
PREMPRO (854 patients)
WARFARIN SODIUM (839 patients)
POTASSIUM CHLORIDE (819 patients)
PAXIL (812 patients)
METOPROLOL TARTRATE (811 patients)
LYRICA (809 patients)
ZYPREXA (807 patients)
LEVOTHYROXINE SODIUM (806 patients)
LEVAQUIN (745 patients)
CYMBALTA (736 patients)
GLYBURIDE (717 patients)
LEXAPRO (714 patients)
DURAGESIC-100 (708 patients)
ZOMETA (702 patients)
COREG (689 patients)
VICODIN (689 patients)
PROZAC (676 patients)
METOPROLOL (675 patients)
ALLOPURINOL (670 patients)
ATIVAN (665 patients)
LOPRESSOR (638 patients)
ACETYLSALICYLIC ACID SRT (629 patients)
AMLODIPINE (622 patients)
LORAZEPAM (617 patients)
METFORMIN (606 patients)
ADVAIR DISKUS 100/50 (591 patients)
ALTACE (589 patients)
ENBREL (587 patients)
CLONIDINE (582 patients)
VITAMIN D (575 patients)
SINGULAIR (555 patients)
COZAAR (553 patients)
GABAPENTIN (551 patients)
DROSPIRENONE AND ETHINYL ESTRADIOL (545 patients)
REVLIMID (540 patients)
TYLENOL (532 patients)
GLIPIZIDE (531 patients)
EFFEXOR (530 patients)
ZANTAC (529 patients)
ALLEGRA (520 patients)
OXYCONTIN (517 patients)
AREDIA (512 patients)
RISPERDAL (511 patients)
ZESTRIL (508 patients)
LORTAB (488 patients)
NUVARING (477 patients)
NAPROXEN (474 patients)
ZYRTEC (474 patients)
CALCIUM (473 patients)
PERCOCET (471 patients)
CELEXA (470 patients)
PROVERA (470 patients)
AGGRENOX (466 patients)
DEXAMETHASONE (464 patients)
FENTANYL (454 patients)
ACTOS (449 patients)
WELLBUTRIN (446 patients)
ALPRAZOLAM (446 patients)
REBIF (444 patients)
AMARYL (444 patients)
LOVENOX (444 patients)
ORTHO EVRA (444 patients)
CLONAZEPAM (439 patients)
RAMIPRIL (434 patients)
PRAVACHOL (432 patients)
FLEXERIL (429 patients)
ENALAPRIL MALEATE (425 patients)
MOTRIN (411 patients)
FLOMAX (405 patients)
PREDNISOLONE (404 patients)
KLONOPIN (404 patients)
ASCORBIC ACID (402 patients)
VANCOMYCIN (399 patients)
PEPCID (398 patients)
CARDIZEM (392 patients)
AMOXICILLIN (391 patients)
VIAGRA (391 patients)
SPIRIVA (390 patients)
ROSIGLITAZONE MALEATE (389 patients)
PREDNISONE TAB (388 patients)
RANITIDINE (382 patients)
EXELON (381 patients)
DIOVAN HCT (379 patients)
MORPHINE (379 patients)
VALIUM (378 patients)
ACCUPRIL (378 patients)
ULTRAM (377 patients)
LANOXIN (376 patients)
MULTI-VITAMIN (376 patients)
METOPROLOL SUCCINATE (374 patients)
VITAMIN E (374 patients)
ZETIA (372 patients)
CHANTIX (372 patients)
LOTREL (371 patients)
SPIRONOLACTONE (371 patients)
VERAPAMIL (370 patients)
PROTAMINE SULFATE (370 patients)
ELAVIL (366 patients)
VITAMINS (UNSPECIFIED) (365 patients)
DIAZEPAM (363 patients)
HUMULIN N (362 patients)
TYSABRI (358 patients)
AMITRIPTYLINE HYDROCHLORIDE (358 patients)
DILANTIN (356 patients)
HYDROCODONE BITARTRATE (350 patients)
MULTI-VITAMINS (346 patients)
GLUCOTROL (344 patients)
EVISTA (340 patients)
HUMULIN R (335 patients)
VYTORIN (334 patients)
BYETTA (334 patients)
TOPAMAX (333 patients)
ZITHROMAX (331 patients)
BENADRYL (327 patients)
AVASTIN (327 patients)
ACIPHEX (327 patients)
CLARITIN (325 patients)
LEVOXYL (322 patients)
TRAMADOL HCL (321 patients)
CEPHALEXIN (320 patients)
ZELNORM (319 patients)
ATACAND (318 patients)
TEGRETOL (315 patients)
PRINIVIL (314 patients)
VASOTEC (314 patients)
FLONASE (314 patients)
NOVOLOG (311 patients)
REGLAN (308 patients)
VITAMIN B-12 (304 patients)
ZOFRAN (298 patients)
IMDUR (298 patients)
COMBIVENT (297 patients)
DEPAKOTE (295 patients)
OXYCODONE HCL (294 patients)
ALEVE (294 patients)
KLOR-CON (294 patients)
AMITRIPTYLINE HCL (293 patients)
CARVEDILOL (293 patients)
PANTOPRAZOLE (291 patients)
EXJADE (290 patients)
COLACE (290 patients)
MECLIZINE (287 patients)
KEPPRA (286 patients)
CALCIUM CARBONATE (286 patients)
CALCIUM (UNSPECIFIED) (285 patients)
HUMULIN 70/30 (283 patients)
VERSED (282 patients)
ARICEPT (281 patients)
HYZAAR (279 patients)
DARVOCET-N 100 (279 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about CEREBROVASCULAR ACCIDENT and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.